Aclaris Therapeutics, Inc.
ACRS
$1.75
-$0.06-3.32%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 1.78M | 1.46M | 9.21M | 4.35M | 2.77M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.78M | 1.46M | 9.21M | 4.35M | 2.77M |
| Cost of Revenue | 13.30M | 13.10M | 18.33M | 8.36M | 10.67M |
| Gross Profit | -11.52M | -11.65M | -9.12M | -4.02M | -7.90M |
| SG&A Expenses | 5.39M | 6.14M | 4.95M | 5.65M | 4.75M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 18.69M | 19.24M | 23.28M | 14.02M | 15.42M |
| Operating Income | -16.91M | -17.78M | -14.07M | -9.67M | -12.65M |
| Income Before Tax | -15.43M | -15.09M | -96.55M | -7.59M | -10.99M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -15.43M | -15.09M | -96.55M | -7.59M | -10.99M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -15.43M | -15.09M | -96.55M | -7.59M | -10.99M |
| EBIT | -16.91M | -17.78M | -14.07M | -9.67M | -12.65M |
| EBITDA | -16.88M | -17.76M | -14.03M | -9.59M | -12.61M |
| EPS Basic | -0.13 | -0.12 | -1.01 | -0.11 | -0.15 |
| Normalized Basic EPS | -0.07 | -0.08 | -0.07 | -0.06 | -0.09 |
| EPS Diluted | -0.13 | -0.12 | -1.01 | -0.11 | -0.15 |
| Normalized Diluted EPS | -0.07 | -0.08 | -0.07 | -0.06 | -0.09 |
| Average Basic Shares Outstanding | 122.58M | 122.39M | 95.31M | 71.38M | 71.29M |
| Average Diluted Shares Outstanding | 122.58M | 122.39M | 95.31M | 71.38M | 71.29M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |